{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:03:26Z","timestamp":1792623806328,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1038\/s41440-022-00855-x","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T03:02:33Z","timestamp":1645066953000},"page":"1028-1036","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Association between dihydropyridine calcium channel blockers and ischemic strokes in patients with nonvalvular atrial fibrillation"],"prefix":"10.1038","volume":"45","author":[{"given":"Fumihiro","family":"Sakakibara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norito","family":"Kinjo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Nezu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"855_CR1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1093\/europace\/eun369","volume":"11","author":"M Nabauer","year":"2009","unstructured":"Nabauer M, Gerth A, Limbourg T, Schneider S, Oeff M, Kirchhof P, et al. The Registry of the German Competence NETwork on Atrial Fibrillation: patient characteristics and initial management. Europace. 2009;11:423\u201334.","journal-title":"Europace."},{"key":"855_CR2","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/HJH.0b013e32834f03bf","volume":"30","author":"AJ Manolis","year":"2012","unstructured":"Manolis AJ, Rosei EA, Coca A, Cifkova R, Erdine SE, Kjeldsen S, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group \u2018Hypertension Arrhythmias and Thrombosis\u2019 of the European Society of Hypertension. J Hypertens. 2012;30:239\u201352.","journal-title":"J Hypertens."},{"key":"855_CR3","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37:2893\u2013962.","journal-title":"Eur Heart J"},{"key":"855_CR4","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/europace\/euq439","volume":"13","author":"T Yamashita","year":"2011","unstructured":"Yamashita T, Inoue H, Okumura K, Kodama I, Aizawa Y, Atarashi H, et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). Europace. 2011;13:473\u20139.","journal-title":"Europace."},{"key":"855_CR5","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1161\/HYPERTENSIONAHA.119.14443","volume":"75","author":"MH Mehlum","year":"2020","unstructured":"Mehlum MH, Liest\u00f8l K, Kjeldsen SE, Wyller TB, Julius S, Rothwell PM, et al. Blood pressure-lowering profiles and clinical effects of angiotensin receptor blockers versus calcium channel blockers. Hypertension. 2020;75:1584\u201392.","journal-title":"Hypertension."},{"key":"855_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.amjhyper.2003.09.008","volume":"17","author":"K Eguchi","year":"2004","unstructured":"Eguchi K, Kario K, Hoshide Y, Hoshide S, Ishikawa J, Morinari M, et al. Comparison of valsartan and amlodipine on ambulatory and morning blood pressure in hypertensive patients. Am J Hypertens. 2004;17:112\u20137.","journal-title":"Am J Hypertens."},{"key":"855_CR7","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1161\/HYPERTENSIONAHA.107.089763","volume":"50","author":"JG Wang","year":"2007","unstructured":"Wang JG, Li Y, Franklin SS, Safar M. Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview. Hypertension. 2007;50:181\u20138.","journal-title":"Hypertension."},{"key":"855_CR8","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, Emdin CA, Kiran A, Anderson SG, Callender T, Emberson J, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet."},{"key":"855_CR9","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1002\/pds.5228","volume":"30","author":"T Morimoto","year":"2021","unstructured":"Morimoto T, Uchida K, Sakakibara F, Kinjo N, Ueda S. Effect of concomitant antiplatelet therapy on ischemic and hemorrhagic events in patients taking oral anticoagulants for nonvalvular atrial fibrillation in daily clinical practice. Pharmacoepidemiol Drug Saf. 2021;30:1321\u201331.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"855_CR10","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021\u2013104.","journal-title":"Eur Heart J"},{"key":"855_CR11","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1111\/j.1751-7176.2011.00513.x","volume":"13","author":"WJ Elliott","year":"2011","unstructured":"Elliott WJ, Ram CV. Calcium channel blockers. J Clin Hypertens. 2011;13:687\u20139.","journal-title":"J Clin Hypertens."},{"key":"855_CR12","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","volume":"285","author":"BF Gage","year":"2001","unstructured":"Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the national registry of atrial fibrillation. Jama. 2001;285:2864\u201370.","journal-title":"Jama."},{"key":"855_CR13","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1378\/chest.10-0134","volume":"138","author":"R Pisters","year":"2010","unstructured":"Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010;138:1093\u2013100.","journal-title":"Chest."},{"key":"855_CR14","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jacc.2014.12.018","volume":"66","author":"KA Hicks","year":"2015","unstructured":"Hicks KA, Tcheng JE, Bozkurt B, Chaitman BR, Cutlip DE, Farb A, et al. 2014 ACC\/AHA Key Data Elements and Definitions for Cardiovascular Endpoint Events in Clinical Trials: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Data Standards (Writing Committee to Develop Cardiovascular Endpoints Data Standards). J Am Coll Cardiol. 2015;66:403\u201369.","journal-title":"J Am Coll Cardiol."},{"key":"855_CR15","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1161\/STR.0b013e318296aeca","volume":"44","author":"RL Sacco","year":"2013","unstructured":"Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, et al. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association\/American Stroke Association. Stroke. 2013;44:2064\u201389.","journal-title":"Stroke."},{"key":"855_CR16","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1161\/STROKEAHA.108.192218","volume":"40","author":"JD Easton","year":"2009","unstructured":"Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association\/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009;40:2276\u201393.","journal-title":"Stroke."},{"key":"855_CR17","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692\u20134.","journal-title":"J Thromb Haemost"},{"key":"855_CR18","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1001\/archneur.1976.00500030062014","volume":"33","author":"JF Butzer","year":"1976","unstructured":"Butzer JF, Cancilla PA, Cornell SH. Computerized axial tomography of intracerebral hematoma. A clinical and neuropathological study. Arch Neurol. 1976;33:206\u201314.","journal-title":"Arch Neurol."},{"key":"855_CR19","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J."},{"key":"855_CR20","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1124\/pr.114.009654","volume":"67","author":"GW Zamponi","year":"2015","unstructured":"Zamponi GW, Striessnig J, Koschak A, Dolphin AC. The physiology, pathology, and pharmacology of voltage-gated calcium channels and their future therapeutic potential. Pharmacol Rev. 2015;67:821\u201370.","journal-title":"Pharmacol Rev."},{"key":"855_CR21","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41440-019-0284-9","volume":"42","author":"S Umemura","year":"2019","unstructured":"Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2019). Hypertens Res. 2019;42:1235\u2013481.","journal-title":"Hypertens Res."},{"key":"855_CR22","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1097\/00004872-200102000-00018","volume":"19","author":"WF Terpstra","year":"2001","unstructured":"Terpstra WF, May JF, Smit AJ, de Graeff PA, Havinga TK, van den Veur E, et al. Long-term effects of amlodipine and lisinopril on left ventricular mass and diastolic function in elderly, previously untreated hypertensive patients: the ELVERA trial. J Hypertens. 2001;19:303\u20139.","journal-title":"J Hypertens."},{"key":"855_CR23","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1161\/STROKEAHA.119.026139","volume":"50","author":"G Siedler","year":"2019","unstructured":"Siedler G, Sommer K, Macha K, Marsch A, Breuer L, Stoll S, et al. Heart failure in ischemic stroke: relevance for acute care and outcome. Stroke. 2019;50:3051\u20136.","journal-title":"Stroke."},{"key":"855_CR24","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1097\/HJH.0b013e3282f4d1d5","volume":"26","author":"DP Papadopoulos","year":"2008","unstructured":"Papadopoulos DP, Papademetriou V. Aggressive blood pressure control and stroke prevention: role of calcium channel blockers. J Hypertens. 2008;26:844\u201352.","journal-title":"J Hypertens."},{"key":"855_CR25","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.clineuro.2007.03.009","volume":"109","author":"G Benbir","year":"2007","unstructured":"Benbir G, Uluduz D, Ince B, Bozluolcay M. Atherothrombotic ischemic stroke in patients with atrial fibrillation. Clin Neurol Neurosurg. 2007;109:485\u201390.","journal-title":"Clin Neurol Neurosurg."}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00855-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00855-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00855-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T11:16:59Z","timestamp":1652440619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-022-00855-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["855"],"URL":"https:\/\/doi.org\/10.1038\/s41440-022-00855-x","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"25 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FS reports paper fees from Medicus Shuppan. SU reports receiving research grants from Bristol-Myers Squibb, Chugai, Kowa, MSD, Pfizer, and Takeda, lecturer fees from Boehringer Ingelheim, MSD, and Taiho, and paper fees from Kowa. He served on an advisory board for Otsuka. KU reports receiving lecturer fees from Daiichi Sankyo, Bristol-Myers Squibb, Stryker, and Medtronic. NK reports receiving lecturer fees from Medtronic and paper fees from Medicus Shuppan. HA and MN have no disclosures to report. TM reports receiving lecturer fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray, receiving paper fees from Bristol-Myers Squibb and Kowa, and served on an advisory board for Sanofi.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Conflict of interest"}},{"value":"The institutional review boards of the University of the Ryukyus (No. 597) and all 71 participating centers approved the study protocol. The institutional review boards waived the need for written informed consent and approved the study following the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}